Summary & Overview

Cardiac Arrest, Unexplained without CC/MCC: Inpatient Reimbursement Overview

DRG 298 applies to unexplained cardiac arrest cases without Major Complication or Comorbidity or Complication or Comorbidity and encompasses admissions where cardiac arrest is the principal diagnosis but no qualifying secondary conditions are present. This grouping matters for inpatient reimbursement because it sets the Centers for Medicare & Medicaid Services prospective payment classification and affects hospital payment for the episode of care.

Cardiac ArrestDRG Cardiac Arrest, Unexplained without CC/MCCDRG 298Diagnosis-Related GroupInpatient ReimbursementMedicareCritical CareResuscitationCardiologyEmergency Medicine

DRG 298 Overview

DRG 298 covers inpatient admissions for unexplained cardiac arrest without Major Complication or Comorbidity or Complication or Comorbidity. This Diagnosis-Related Group captures cases where cardiac arrest is the principal diagnosis but no additional major or secondary complicating conditions are coded. It matters for Medicare payment because case assignment to DRG 298 determines the base prospective payment amount for the hospital stay and influences resource classification for billing. Accurate coding and documentation affect grouping and reimbursement under Centers for Medicare & Medicaid Services inpatient prospective payment policies.

Clinical Trials

Acute resuscitation interventions: randomized or pilot studies testing timing, protocols, or devices used during in-hospital or out-of-hospital cardiac arrest resuscitation (for example, comparing advanced airway strategies, titrated vasopressor use, or mechanical CPR adjuncts). These studies focus on the immediate arrest population including adults who experience unexplained cardiac arrest without clear comorbid complications, aiming to improve return of spontaneous circulation and early survival. Results are directly relevant to hospitals and payers because changes in resuscitation practice can alter ICU stay duration, resource intensity, and early mortality rates for this DRG.
Diagnostic and prognostic evaluation studies: observational cohorts and prospective diagnostic accuracy research evaluating post-arrest workups such as cardiac imaging protocols, continuous ECG monitoring, genetic testing panels, and biomarker strategies to identify occult causes of unexplained arrest. These trials enroll survivors of unexplained cardiac arrest who are hemodynamically stabilized and seek to stratify risk, identify underlying arrhythmogenic or structural etiologies, and predict neurological and cardiac outcomes. Findings inform targeted downstream care pathways, utilization of specialty testing, and reimbursement decisions around costly diagnostics that affect length of stay and readmission risk.
Post-discharge functional and secondary prevention trials: comparative effectiveness or pragmatic trials examining rehabilitation intensity, implantable monitoring strategies, or structured secondary prevention programs (including medication adherence support and remote monitoring) among survivors discharged after unexplained cardiac arrest. These studies enroll patients post-hospitalization to measure long-term survival, recurrent arrest or arrhythmia events, functional recovery, and health-care utilization. Payers and providers use this evidence to design follow-up care bundles, allocate resources for outpatient monitoring or rehabilitation, and potentially reduce costly readmissions tied to this DRG.

Related Codes

291-HEART-FAILURE-AND-SHOCK-WITH-MCC

Heart Failure and Shock with MCC: Inpatient Reimbursement Overview

229-OTHER-CARDIOTHORACIC-PROCEDURES-WITHOUT-MCC

Other Cardiothoracic Procedures without MCC: Inpatient Reimbursement Overview

234-CORONARY-BYPASS-WITH-CARDIAC-CATHETERIZATION-OR-OPEN-ABLATION-WITHOUT-MCC

Coronary Bypass with Cardiac Catheterization or Open Ablation without MCC: Inpatient Reimbursement Overview

265-AICD-LEAD-PROCEDURES

AICD Lead Procedures: Inpatient Reimbursement Overview

288-ACUTE-AND-SUBACUTE-ENDOCARDITIS-WITH-MCC

Acute and Subacute Endocarditis with MCC: Inpatient Reimbursement Overview

280-ACUTE-MYOCARDIAL-INFARCTION-DISCHARGED-ALIVE-WITH-MCC

Acute Myocardial Infarction, Discharged Alive with MCC: Inpatient Reimbursement Overview

289-ACUTE-AND-SUBACUTE-ENDOCARDITIS-WITH-CC

Acute and Subacute Endocarditis with CC: Inpatient Reimbursement Overview

233-CORONARY-BYPASS-WITH-CARDIAC-CATHETERIZATION-OR-OPEN-ABLATION-WITH-MCC

Coronary Bypass with Cardiac Catheterization or Open Ablation with MCC: Inpatient Reimbursement Overview

277-CARDIAC-DEFIBRILLATOR-IMPLANT-WITHOUT-MCC

Cardiac Defibrillator Implant without MCC: Inpatient Reimbursement Overview

232-CORONARY-BYPASS-WITH-PTCA-WITHOUT-MCC

Coronary Bypass with PTCA without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.